SS-31 (Elamipretide) was shown to displace α-synuclein from lipid membranes, inhibit its membrane-induced aggregation, and reduce the harmful effects of α-synuclein oligomers in neuroblastoma cells by restoring mitochondrial function and blocking oligomer uptake. The findings suggest SS-31 warrants further development as a peptide-based intervention against α-synuclein-mediated pathology.
Journal article — In vitro and cell-based experimental study. Population: Human neuroblastoma cells and negatively charged small unilamellar vesicles. Interventions: SS-31 (Elamipretide).
SS-31 displaced both wild-type and N-terminal acetylated α-synuclein from negatively charged small unilamellar vesicles in a dose-dependent manner, as shown by fluorescence correlation spectroscopy and fluorescence anisotropy. It inhibited membrane-induced α-synuclein aggregation and changed fibril morphology in Thioflavin-T and electron microscopy assays. In neuroblastoma cells treated with α-synuclein oligomers, SS-31 enhanced cell viability and restored impaired mitochondrial function. Confocal imaging showed that SS-31 reduced cellular uptake of α-synuclein oligomers. No quantitative effect sizes, doses, or sample numbers are reported in the abstract.
For researchers working on SS-31, this paper broadens its known mitochondrial-targeted activity to a new membrane-centric mechanism: displacing α-synuclein from lipid surfaces, blocking its aggregation, and preventing oligomer uptake into cells. It does not establish in vivo efficacy, dosing, or any effect on Parkinson's disease progression in animal models or patients.
Peptide profiles: SS-31.
All indexed evidence: SS-31 trials & papers.
Related studies: Pre-qualifications, learning strategies, and study satisfaction among medical students:…, Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence, Elamipretide: a mitochondria-targeting drug for Barth syndrome, Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets….